

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Zavegepant. [Updated 2023 Apr 15]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Zavegepant Revised: April 15, 2023.

CASRN: 1337918-83-8

Drug Levels and Effects

Summary of Use during Lactation

There is no published experience with zavegepant during breastfeeding. Zavegepant is 90% protein bound, so levels in milk are likely low. If zavegepant is required by the mother of an older infant, it is not a reason to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Eletriptan, Rizatriptan, Sumatriptan, Zolmitriptan

Substance Identification

Substance Name

Zavegepant

CAS Registry Number

1337918-83-8

Drug Class

Breast Feeding

Lactation

Milk, Human

Analgesics

Calcitonin Gene-Related Peptide Receptor Antagonists

CGRP-R Inhibitors